The GLP-1 Guide
How GLP-1 therapies work, what the trials show for weight and metabolic health, the real trade-offs, and the questions still unanswered.
GLP-1 receptor agonists are the most consequential metabolic drugs in a generation. This guide explains what they do, what the evidence supports, and how to think about the trade-offs honestly.
What GLP-1 does in the body
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does several things at once:
- Slows stomach emptying, so you feel full longer
- Signals the brain to reduce appetite
- Stimulates insulin and suppresses glucagon, improving blood-sugar control
GLP-1 medications are engineered versions that last far longer than the natural hormone — turning a brief post-meal signal into a steady one.
What the trials show
The human evidence here is unusually strong:
In large randomized trials, GLP-1 agonists produced clinically significant weight loss and improved metabolic markers — and newer cardiovascular outcome data suggests benefits beyond weight alone.
For the cardiovascular angle specifically, see our breakdown of what the SELECT trial actually showed.
The trade-offs
No honest guide skips these:
- Side effects — nausea and GI symptoms are common, especially during dose escalation
- Muscle loss — rapid weight loss includes lean mass; resistance training and protein matter
- Durability — stopping often leads to regain; these are management tools, not one-time cures
- Cost and access — real-world barriers that shape who benefits
How to think about it
GLP-1 therapy is a genuine breakthrough and a tool with real costs. The people who do best treat it as one part of a system — training, protein, sleep — not a replacement for it.
Where to go next
Browse the latest GLP-1 and metabolic research, or start with the Recovery Guide to protect lean mass while losing fat.
This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.